Trial Profile
Patient Characteristics and Bleeding Events in Non-Valvular Atrial Fibrillation Patients Treated with Apixaban or Vitamin K Antagonists: Real-World Study in Italy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Oct 2017
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Vitamin K antagonists
- Indications Embolism and thrombosis
- Focus Adverse reactions
- 08 Nov 2017 Results presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 23 Oct 2017 New trial record